β Home
© 2024 - 2025 InsightfulValue.com. All rights reserved.
βΉοΈ Info
π§Ύ At a Glance π Core Facts ποΈ Products/Services β Ratings π§βπΌ Executives π¬ My Commentsπ‘ Analytics
π Insights π’ Company Q&A (464) π οΈ Industry Q&A (98) π Competitors π Price Low π Price Swings β‘ SWOT ποΈ PEST π Porter's Five Forces β¨ Score Positive β οΈ Risk Assessment π§© Segmentation π Ά Google Linksπ Ratios
π° Margins π Financial Ratios π± Growth π Enterprise Value π Key Metrics π΅ Dividendsπ§ Tools
β Due Diligenceπ§© Revenue Segmentation by Product
Switch to Location
Fiscal year | Segment | Value |
---|---|---|
2024 | Elaprase | 91.56B |
2024 | Adderall XR | 41.76B |
2024 | Other Rare Hematology | 47.3B |
2024 | Oncology | 462.36B |
2024 | Immunoglobulin | 644.59B |
2024 | PDT Immunology | 818.57B |
2024 | Velcade | 5.54B |
2024 | Takhzyro | 178.68B |
2024 | Leuplin/Enantone | 107.35B |

π° Explore more revenue segmentation data for Takeda Pharmaceutical!
Sign up for free or log inπ Join now to get "The Checklist Value Investor β A Smarter Way to Pick Stocks" at no cost